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The healing response of blood vessels from the vascular
injury induced by therapeutic interventions is charac-
terized by increased cellularity and tissue remodeling.
Frequently, this leads to intimal hyperplasia and lumen
narrowing, with significant clinical sequelae. Vascular
smooth muscle cells are the primary cell type involved
in this process, wherein they express a dedifferentiated
phenotype that transiently resembles neoplastic trans-
formation. Recent studies have highlighted the role of
mitochondrial proteins, such as the molecular chaper-
one heat shock protein-90 (Hsp90), in promoting can-
cer cell survival, which leads to new candidate chemo-
therapeutic agents for neoplastic disease. Herein, we
identify mitochondrial Hsp90 as a key modulator of the
vascular injury response. Hsp90 expression is up-regu-
lated in injured arteries and colocalizes with the apop-
tosis inhibitor, survivin, in vascular smooth muscle cell
in vitro and in vivo. By using a proteomic approach, we
demonstrate that targeted disruption of mitochondrial
Hsp90 chaperone function in vascular smooth muscle
cell leads to loss of cytoprotective client proteins (sur-
vivin and Akt), induces mitochondrial permeability, and
leads to apoptotic cell death. Hsp90 targeting using a cell-
permeable peptidomimetic agent resulted in marked at-
tenuation of neointimal lesions in amurine arterial injury
model. These findings suggest that mitochondrial Hsp90
chaperone function is an important regulator of intimalhyperplasia and may have implications for molecular
strategies that promote the long-term patency of cardio-
vascular interventions. (Am J Pathol 2012, 181:1151–1157;
http://dx.doi.org/10.1016/j.ajpath.2012.06.023)
Intimal hyperplasia (IH) is a vaso-occlusive pathological
process that limits the efficacy of cardiovascular interven-
tions, including angioplasty, stenting, and surgical by-
pass. It is characterized by increased cellularity in the
vessel wall, dominated by an expansion of dedifferenti-
ated vascular smooth muscle cells (VSMCs).1 The mech-
anisms regulating IH involve multiple signaling pathways
that collectively alter VSMC phenotype. The end result is
a temporal and spatial disparity between proliferation
and apoptosis that may lead to excessive tissue expan-
sion and lumen compromise.
The 90-kDa heat shock protein-90 (Hsp90) is a highly
abundant cellular protein that is a key molecular chaper-
one associated with cell cycle regulation and apoptotic
pathways.2,3 In cancer cells, direct interaction between
Hsp90 and its client proteins appears central to maintaining
an apoptosis-resistant cell phenotype, and has become a
target for cancer therapeutics.4–6 The role of Hsp90 in vas-
cular injury is less well established. However, it has been
recently implicated in a pro-inflammatory phenotype of
VSMCs7 and in the pathogenesis of atherosclerosis.8 We
hypothesize that neointimal VSMCs transiently use molecu-
lar pathways of proliferation and apoptosis resistance, sim-
ilar to neoplasia. We, therefore, investigated whether dis-
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survival circuits that may be essential to IH.
Shepherdin is a candidate anticancer molecule that is
a direct inhibitor of Hsp90 chaperone function. It is a
biotinylated, cell-permeable, retro-inverso peptidomi-
metic molecule incorporating residues 79 to 87 of the
inhibitor of apoptosis protein survivin (SVV), an Hsp90
client. This sequence was identified as a minimal se-
quence of SVV that interacts with the ATP-dependent
binding pocket of Hsp90, and its presence has compet-
itively inhibited the HSP90 chaperone function of SVV.5
SVV is an important regulator of cell cycle progression
and inhibits apoptosis. It has had a role in both cancer
and IH. In particular, disruption of Hsp90 chaperone
function by shepherdin induces apoptosis in multiple
cancer cell lines.4,9–11 Shepherdin has been designed as
a specific inhibitor of the SVV-Hsp90 interaction. In addi-
tion, there is evidence that it also inhibits Hsp90 chaper-
one function involving Akt. Furthermore, subcellular pools
of Hsp90, particularly in the mitochondria, have demon-
strated a central role in the regulation of tumor cell
growth.12,13 More importantly, the targeting of mitochon-
drial fractions of Hsp90 by shepherdin in prostate cancer
and glioblastoma cells has demonstrated tumor cell kill-
ing in vitro and in vivo.14 In this study, we investigate the
role of mitochondrial Hsp90 in regulating VSMC survival
pathways that may contribute to IH after vascular injury.
Materials and Methods
Cell Isolation and Culture
Primary human VSMC (HVSMC) cultures were estab-
lished from discarded saphenous vein segments after
cardiac or vascular surgical procedures using an explant
protocol, as previously described.10 Primary rabbit aortic
VSMC cultures were established by explant culture of
thoracic aorta from New Zealand white rabbits. Cells
were used in passages 2 to 6.
Peptidomimetics
All peptides were synthesized by the W. M. Keck Bio-
technology Research Center at Yale University School of
Medicine.5 The SVV sequence K79-L87 (KHSSGCAFL)
was attached to a cell-permeable Antennapedia home-
odomain (italicized sequence following) in a retro-inverso
sequence, resulting in the final sequence: free/biotin-
RQIKIWFQNRRMKWKKLFACGSSHK-COOH. Similarly, a
scrambled peptide (SKLACFSHG) was constructed to
serve as a control with the sequence free/biotin-RQIKI-
WFQNRRMKWKKGHSFCALKS-COOH. Reconstituted pep-
tides were diluted under sterile conditions for in vitro and in
vivo experiments.
Cell Viability Assay
A total of 40,000 VSMCs per treatment group were treated
with or without peptide for 8 hours. An MTT viability assay
was performed per manufacturer’s instructions (TOX1 as-
say; Sigma-Aldrich, St. Louis, MO). For experiments usingcyclosporin A (CsA), cells were incubated for 24 hours in 1
mol/L CsA before treatments, as noted.
DNA Content Analysis
Peptide-treated HVSMCs were fixed, stained with pro-
pidium iodide (0.5 mg/mL; Roche Diagnostics, Indianapo-
lis, IN), and analyzed for DNA content by flow cytometry
(FACScalibur; Becton Dickinson, Franklin Lakes, NJ). Data
analysis was performed with FlowJo (Tree Star, Ashland, OR).
Annexin V Assay
VSMCs were seeded into a four-chamber cell culture slide
(Nalge Nunc International, Rochester, NY) at 75% conflu-
ence; treated with peptide for 8 hours; stained for annexin V,
per manufacturer’s instructions (BioVision, Mountain View,
CA); and imaged via fluorescence microscopy.
Co-Immunoprecipitation
Total protein lysate, 300 g, was collected from 3 million
HVSMCs and incubated with 5 mg/mL anti-SVV rabbit
polyclonal antibody (Novus Biologicals, Littleton, CO) at
4°C for 12 hours. Bound protein was precipitated with
protein A slurry at 4°C. After washing and boiling the
bound fraction, all fractions were assayed using Western
blot analysis, as described later.
In Vitro Shepherdin Assay andWestern Blot
Analysis
VSMCs were plated at 75% confluence; after 24 hours, they
were treated with either shepherdin or scrambled peptide
for 8 hours, followed by harvesting and lysis in the presence
of protease inhibitor (Sigma-Aldrich). The lysate superna-
tant was extracted by centrifugation, and protein concen-
trations were checked by modified Lowry assay (Detergent
Compatible Assay; Bio-Rad, Hercules, CA), per manufac-
turer’s instructions. Total protein, 30 g per plate, was sep-
arated by SDS-PAGE gel and transferred to a polyvi-
nylidene difluoride membrane using a semidry technique
(Bio-Rad). The membrane was incubated overnight at 4°C
with primary antibodies [anti-SVV, 1:1000 (Novus Biologi-
cals); anti-Akt, 1:1000 (Santa Cruz Biotechnology, Santa
Cruz, CA); anti-Hsp90, 1:1000 (Becton Dickinson); and anti-
-actin, 1:2500 (Sigma-Aldrich)], followed by correspond-
ing secondary antibody. Bands were detected using Super-
Signal Pico chemiluminescence reagent (Pierce, Rockford,
IL), according to the manufacturer’s instructions.
Subcellular Protein Fractionation
HVSMC lysates were fractionated into cytosolic and mi-
tochondrial fractions for Western blot analysis using the
Qproteome Mitochondria Isolation Kit (Qiagen, Valencia,
CA). After separation by SDS-PAGE gel and membrane
transfer, the membranes were probed to quantify protein
expression of Hsp90 (Cell Signaling Technology, Dan-
vers, MA) and SVV (Santa Cruz Biotechnology). Glycer-
aldehyde-3-phosphate dehydrogenase (Santa Cruz Bio-
technology) and cytochrome C (Clontech, Mountain
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tein loading controls, respectively.
JC-1 Assay
The JC-1 potentiometric dye (Invitrogen, Carlsbad, CA)
was used to measure mitochondrial membrane potential.
HVSMCs were cultured in Dulbecco’s modified Eagle’s
media with 0.5% fetal bovine serum, 5 mol/L 17-allyl-
amino-17-demethoxygeldamycin (17-AAG), 50 nmol/L
shepherdin, 50 nmol/L scrambled peptide, or 50 mol/L
peroxynitrite for 24 hours. Cells were treated with JC-1 dye
and analyzed using flow cytometry, per manufacturer’s in-
structions. Mitochondrial membrane potential was esti-
mated by calculating a ratio of red/green fluorescence.
Balloon Injury and Local Peptidomimetic
Delivery in Rabbits
All animal experiments were performed in accordance with
the standards of the Harvard Medical Area Standing Com-
mittee on Animals. New Zealand white rabbits (Charles
River Laboratories, Wilmington, MA), weighing 3.0 to 3.5 kg,
underwent bilateral external iliac artery injury with a number
2 Fogarty balloon.10 A 40% Pluronic gel F127 matrix (BASF,
Florham Park, NJ), with or without 50 to 250 mol/L shep-
herdin, was applied to the external iliac artery segment. The
external iliac arteries were harvested at days 3 and 5 post-
operatively for evaluating the early vessel changes (via
cryosectioning) or at day 28 for evaluating IH (via 80 to 100
mmHg, 10% normal-buffered formalin perfusion fixation,
paraffin embedding, and sectioning).
Figure 1. Hsp90 and SVV associate in VSMCs, and the targeted disruption o
rabbit iliac artery demonstrates predominant Hsp90 staining in the arterial int
expression in the media and inner adventitial layers. C: Hsp90 expression aft
yellow, colocalized red and green fluorescence; blue, nuclei; red arrows, int
of positive cells; white arrows in the insets point to the same cell as the w
D: Hsp90 and SVV interaction in VSMCs is shown by co-immunoprecip
experiments. E: Treatment of VSMCs with shepherdin for 8 hours leads to de
Loss of VSMC viability with 8-hour shepherdin exposure by MTT assay, compared w
of apoptosis in VSMCs, as evaluated by DNA content flow cytometry after 6-hour sWire Injury and Systemic Peptidomimetic
Delivery in Mice
Male C57BL/6 mice, aged 8 to 10 weeks and weighing 20
to 30 g (Charles River Laboratories), underwent common
femoral artery injury via exposure of the superficial fem-
oral artery using six passes of a 0.014-inch diameter
angioplasty guide wire (CROSS-IT 100 XT; Abbott Vas-
cular, Santa Clara, CA). The arteriotomy site in the super-
ficial femoral artery was subsequently ligated. For the first
postoperative set, day 14 after injury, mice were admin-
istered 50 mg/kg shepherdin or vehicle (saline) via i.p.
injection. At day 21 after injury, the mice were euthanized
and perfusion fixed with 10% normal-buffered formalin.
The injured common femoral artery was harvested and
processed into paraffin for sectioning.
Immunofluorescent Staining and TUNEL Assay
All of the immunofluorescent staining was completed on
frozen sections (6 m thick) fixed by ice cold acetone for 10
minutes. Goat anti-mouse IgG, conjugated with Alexa Fluor
488 or 568 (1:150, respectively; Invitrogen), was selected
as secondary antibody. Mouse IgG1 (number MAB002;
R&D Systems, Minneapolis, MN) or IgG2a,  (number
NB600-986; Novus Biologicals) was used as isotype nega-
tive control. Hsp90 (AC88 anti-Hsp90, 1:100, number
ab13492; Abcam, Cambridge, MA) in vivo–localized ex-
pression or colocalization with SVV (anti-SVV, 1:500, num-
ber NB500-205; Novus Biologicals) was examined on day 5
injured rabbit iliac arteries. Anti-Ki-67 (1:100, number NCL-
Ki-67-MM1; Novocastra Laboratories, Newcastle Upon
teraction with shepherdin rapidly induces apoptotic cell death. A: Uninjured
t day 3 after balloon injury, rabbit iliac arteries demonstrate increased Hsp90
n injury localizes extensively with SVV. A–C: Bright green, Hsp90; red, SVV;
stic lamina; yellow arrows, external elastic lamina;white arrows, samples
rrows in A–C at a higher resolution. (L), vessel lumen. Scale bar  50 m.
b, bound fraction; u, unbound fraction. Data are representative of three






gradatioith a scrambled peptide (n  6). **P  0.01. G: Dose-dependent induction
hepherdin treatment. **P  0.01.
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penetration and viability of biotinylated shepherdin were
assessed via Alexa Fluor 594–conjugated streptavidin (1:
400; Invitrogen). The apoptosis TUNEL assay was used on
4% paraformaldehyde fixed frozen sections, using in situ
cell death detection kit fluorescein (number 11684795910;
Roche Diagnostics), per manufacturer’s instructions. DAPI
(1 g/mL, number D1306; Invitrogen) nuclear counterstain-
ing was used on all of the immunofluorescent staining and
TUNEL assay.
Image Acquisition and Measurements
Photography was completed via a Nikon Eclipse 80i flu-
orescent microscope (Nikon Instruments, Melville, NY),
with SPOT RTke Camera and SPOT Windows version
4.1.2 software (Diagnostic Instruments, Sterling Heigths,
MI). Four vessel zones (original magnification, 200)
were selected randomly on four coordinate axes of every
stained rabbit arterial cross section. The proportion of
Ki-67– or TUNEL-positive cells was calculated by abso-
lute positive cell number/DAPI-positive nuclei.
Elastin Staining
Modified Verhoeff–Van Gieson elastic staining was per-
formed on day 28 rabbit iliac arterial and day 21 mousefemoral arterial cross sections. Lumen circumference,
internal elastic lamina, and external elastic lamina were
delineated by hand, and planimetry was completed by
AxioVision Rel 4.4 software (Carl Zeiss, Oberkocken,
Germany).
Statistical Analysis
Data are expressed as mean  SEM, where appropriate.
Statistical tests were completed with Stata/IC version
10.0 (StataCorp LP, College Station, TX). Differences
among more than two groups were analyzed by one-way
analysis of variance. A comparison for two homogeneous
groups was performed via a two-tailed paired Student’s
t-test. P  0.05 was considered statistically significant.
Results
Hsp90 Is a Chaperone of SVV in VSMCs and
Disruption by Shepherdin Results in Apoptotic
Cell Death
In the healthy arterial wall, Hsp90 was prominently ex-
pressed in the intima (Figure 1A), where it has been
associated with the regulation of endothelial nitric oxide
Figure 2. A mitochondrial Hsp90-SVV complex
modulates organelle injury and is cytoprotective
in VSMCs. A: Mitochondrial stabilization of
VSMCs with CsA preserves cell viability in the
presence of shepherdin. *P  0.05. Rapid mito-
chondrial depolarization after exposure to 50
nmol/L shepherdin (B, n  6, analysis of vari-
ance P  0.05, and *P  0.05) demonstrated by
red to green fluorescence shift in JC-1 assay (C).
Representative JC-1 assay showing red to green
dye shift consistent with mitochondrial permea-
bility. D: Representative Western blot analysis
demonstrating mitochondrial pool of SVV that is
increased after 24-hour exposure to platelet-de-
rived growth factor–BB (100 ng/mL). GAPDH,
glyceraldehyde-3-phosphate dehydrogenase.
Mitochondrial Hsp90 and Vascular Injury 1155
AJP October 2012, Vol. 181, No. 4synthase.15 After arterial balloon injury in the rabbit,
Hsp90 expression increased in all layers of the arterial
wall, including within the VSMC-rich medial layer of the
artery (Figure 1B). The highly abundant expression of
Hsp90 demonstrated extensive colocalization with SVV
(Figure 1C). Immunoprecipitation of protein lysates from
primary cultured HVSMCs with an anti-SVV antibody dem-
onstrated Hsp90 in the precipitate, confirming direct inter-
action between Hsp90 and SVV in these cells (Figure 1D).
Shepherdin rapidly accumulated intracellularly in a
broad spectrum of cell types,16 including HVSMCs (see
Supplemental Figure S1 at http://ajp.amjpathol.org).
Western blot analysis demonstrated that shepherdin
treatment of HVSMCs led to a rapid, dose-dependent
degradation of the Hsp90 client proteins SVV and Akt,
whereas treatment with a scrambled control peptide did
not decrease these proteins (Figure 1E). Exposure of
HVSMCs to a 120 mol/L dose of shepherdin for 8 hours
resulted in a 60%  11% loss of viability compared with
scrambled (control) peptide, which demonstrated 23%
5% loss of viability (P  0.01) by MTT assay. This se-
quence-specific cytotoxicity was dose dependent (Fig-
ure 1F). Similar dose-dependent cell death was seen in
primary cultured rabbit aortic VSMCs (eg, 34% versus
2% loss of viability at 80 mol/L shepherdin versus
scrambled peptide; data not shown). To capture the cell
death mechanisms at an early time point, HVSMCs were
exposed to peptides (40, 80, or 120 mol/L) for 6 hours.
Figure 3. Targeted disruption of Hsp90-SVV with shepherdin modulates th
shepherdin peptide is applied to the adventitial surface of the injured segmen
injury. A: Streptavidin staining for the biotinylated shepherdin peptide demo
Ki-67 staining of shepherdin-treated vessels demonstrates attenuation of the p
C: TUNEL assay of shepherdin-treated vessels demonstrates increased apopt
of shepherdin (50 mg/kg) after iliac artery wire injury in mice (n 6) results in marke
yellow arrows, external elastic lamina (EEL). Scale bars: 50 m (A–C); 500 m (DDNA content analysis showed a significant increase in
the apoptotic fraction at both 80 and 120 mol/L doses of
shepherdin (P  0.01, Figure 1G). Annexin V staining
after 8-hour exposure to shepherdin provided qualitative
confirmation of apoptosis induction in VSMCs (see Sup-
plemental Figure S2 at http://ajp.amjpathol.org). In con-
trast, treatment of VSMCs with the Hsp90 inhibitor 17-
AAG at doses shown in cancer cells to induce apoptosis
(5 mol/L)17 did not initiate VSMC cell death (Figure 1G).
Any appreciable loss of VSMC viability (22%) was ob-
served only at high concentrations of 17-AAG (120
mol/L) (data not shown), similar to the degree seen with
scrambled peptide.
Mitochondrial Hsp90 and SVV Modulated
Organelle Injury and Are Cytoprotective in
VSMCs
The differential potency between two Hsp90 inhibitors in
cancer, shepherdin and 17-AAG, was postulated to re-
late to subcellular pools of Hsp90 and SVV with distinct
functions.5 Unlike 17-AAG, the cell-permeability (anten-
napedia) domain of shepherdin allowed rapid penetra-
tion of the mitochondrial envelope. Mitochondrial-specific
Hsp90 chaperone function was critical for survival of ma-
lignant cells.12 To investigate the possibility of a similar
relationship in VSMC survival, we blocked the mitochon-
lar injury response in vivo. A–C: After iliac artery balloon injury in rabbits,
uronic gel vehicle. (L), vessel lumen. The following results are for day 5 after
diffusion into the media of the vessel wall. Red, shepherdin; blue, nuclei. B:
y proliferative response (n  9). *P  0.05. Bright green, Ki-67; blue, nuclei.
9). *P  0.06. Bright green, TUNEL; blue, nuclei. D: Systemic, i.p. deliverye vascu
t in a Pl
nstrates
ostinjur
osis (n d attenuation of IH at day 21. *P 0.05. Red arrows, internal elastic lumen;
).
1156 Hoel et al
AJP October 2012, Vol. 181, No. 4drial pore complex in VSMCs with the cyclophilin D in-
hibitor, CsA. Pretreatment of VSMCs with CsA abrogated
the shepherdin-induced loss of viability by MTT assay
(Figure 2A). Direct measurement of mitochondrial mem-
brane potential in cultured VSMCs confirmed that a rapid
depolarization occurred with exposure to shepherdin,
similar to that observed after short-term exposure to per-
oxynitrite, and not seen with 17-AAG or scrambled pep-
tide (Figure 2, B and C). Subcellular protein fractionations
demonstrated that most total cellular SVV resided within
the mitochondrial compartment of cultured VSMCs. No-
tably, this mitochondrial SVV pool was up-regulated by
the prototypic vascular growth factor, platelet-derived
growth factor–BB (Figure 2D), which promoted VSMC
activation and was established as a mediator of IH.18,19
Our data suggested that mitochondrial Hsp90 and SVV
functioned as important regulators of mitochondrial ho-
meostasis and cytoprotection in VSMCs.
Modulation of Injury Response, VSMC Survival,
and IH in Rabbits and Mice
We examined the in vivo relevance of Hsp90 chaperone
function in two established animal models of vascular
injury. In the first model, balloon injury of rabbit iliac artery
was performed, followed directly by local, peri-adventitial
application of shepherdin (50 to 250 mol/L) in 40%
Pluronic gel to the vessel. Fluorescence microscopy at
day 5 after the procedure demonstrated circumferential
delivery with penetration of peptide into the vessel wall to
the tunica media (Figure 3A). Dose-ranging experiments
demonstrated an increase of vessel wall staining intensity
at 100 and 250 mol/L, with a similar extent of penetration
(data not shown). Five days after injury, shepherdin-
treated arteries demonstrated a 40% reduction in cell
proliferation by Ki-67 staining compared with control ar-
teries exposed to Pluronic gel alone (n  9, P  0.05,
Figure 3B). The TUNEL assay demonstrated a concomi-
tant 33% increase in apoptosis in the media and adven-
titial layers under the same conditions (P  0.06, Figure
3C). The development of IH in this rabbit model was
evaluated at day 28 after angioplasty (n  7), and dem-
onstrated a nonsignificant reduction in intimal thickness
(60.52  10.42 m for shepherdin versus 67.65  8.58
m for control; P  0.61) and intimal/medial thickness
ratio (0.98  0.09 for shepherdin versus 1.18  0.17 for
control; P  0.33). Because we observed a robust effect
on the early cellular response, we hypothesized that a
single, local application of peptide to the adventitia might
be inadequate to fully exploit mitochondrial Hsp90 inhi-
bition in this model. This was supported by the incom-
plete intracellular delivery of shepherdin to the vessel
media, as shown in Figure 3A. Therefore, we next took a
multiple-dose systemic delivery approach previously es-
tablished in a malignancy model13 and applied it to a
murine model of arterial injury. After unilateral common
femoral artery wire injury, male C57BL/6 mice were
treated with daily i.p. injections of either 50 mg/kg shep-
herdin or saline (n 6 per group) for 14 days. Analysis of
arterial segments harvested 21 days after injury demon-strated a marked (95%) attenuation of IH in the shepher-
din-treated mice (P  0.05, Figure 3D).
Discussion
Previous work has suggested that VSMCs temporally ex-
press an apoptosis-resistant phenotype that may directly
contribute to the pathogenesis of vasoproliferative disor-
ders, such as IH and atherosclerosis.20 Furthermore, the
persistence of this phenotype in isolated VSMC culture21
readily allows study of their cellular mechanisms. In neo-
plasia, a mitochondrial pool of Hsp90 is critical to the
cellular stress response, and is required to maintain mi-
tochondrial integrity.22 After acute vascular injury,
VSMCs in the vessel wall are subject to a host of inflam-
matory, proliferative, and anti-apoptotic signals that are
integrated in the early phase of healing. Herein, we dem-
onstrate the importance of a mitochondrial cytoprotective
protein complex including Hsp90 in the regulation of this
short-term response. Growth factors and inflammatory
cytokines generated locally may directly modulate the
activity of this mitochondrial protein network. Because IH
represents the net effect of alterations in cell survival,
proliferation, and matrix metabolism, this pathway may
be an important regulator of lesion development. We
demonstrate that this organelle-specific network may be
selectively exploited by mitochondrial targeting of Hsp90
chaperone activity in VSMCs using a proteomic ap-
proach. Therefore, modulation of mitochondrial mem-
brane integrity in VSMCs may represent an important new
avenue of investigation for anti-restenosis therapies.
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